Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Primary Tumor Resection Combined With Osimertinib in Patients With Advanced EGFR-mutant Non-small Cell Lung Cancer: A Randomized Controlled Study

NCT07177092 is registered in ClinicalTrials.gov with Jianxing He as lead sponsor.

NCT NCT07177092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Primary Tumor Resection Combined With Osimertinib in Patients With Advanced EGFR-mutant Non-small Cell Lung Cancer: A Randomized Controlled Study
Lead sponsor
Jianxing He
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 8, 2025
Completion date
December 1, 2030
Enrollment
118 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, non-small cell lung cancer